Market Cap 9.79B
Revenue (ttm) 147.66B
Net Income (ttm) -8.64B
EPS (ttm) N/A
PE Ratio 5.24
Forward PE 6.81
Profit Margin -5.85%
Debt to Equity Ratio 0.92
Volume 13,458,801
Avg Vol 9,747,166
Day's Range N/A - N/A
Shares Out 865.56M
Stochastic %K 31%
Beta 0.78
Analysts Sell
Price Target $11.39

Company Profile

Walgreens Boots Alliance, Inc. operates as a healthcare, pharmacy, and retail company in the United States, Germany, the United Kingdom, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merch...

Industry: Pharmaceutical Retailers
Sector: Healthcare
Phone: 847 315 3700
Address:
108 Wilmot Road, Deerfield, United States
ChessGM
ChessGM Jun. 20 at 11:41 PM
$WBA "Heads up alert! upcoming earnings on Thursday, 6/26/2025 for $WBA Neutral (5.5) In recent evaluations of Walgreens Boots Alliance (WBA), the company faces significant challenges and strategic shifts as it moves towards privatization following a definitive agreement with Sycamore Partners valued at $23.7 billion. The transaction is positioned as a means to revitalize a company that has seen its market capitalization shrink dramatically from its peak. Key financial metrics for WBA reveal a Price-to-Earnings (P/E) ratio that reflects a struggling retail environment. The company has reported earnings per share (EPS) growth that has been inconsistent, with analysts projecting modest revenue forecasts as it navigates a competitive landscape against peers like CVS and Rite Aid. Walgreens has also struggled with operational efficiency and strategic missteps that have contributed to a decade of stagnation. However, its recent push towards automation and the expansion of micro-fulfillment centers could signal a shift in operational strategy that might enhance its efficiency and service delivery. Regarding upcoming earnings reports, analysts are cautiously optimistic. Historical performance shows a mixed bag, with some quarters outperforming expectations while others have underwhelmed. Analyst consensus estimates indicate that the upcoming earnings report may reflect a slight improvement in revenue, driven by cost-saving initiatives and increased automation in pharmacy operations. However, the overall sentiment suggests that while there may be a recovery in certain metrics, the potential impact of the acquisition and the need for a robust turnaround strategy weigh heavily on future performance. The healthcare retail sector, in which WBA operates, has shown resilience with a recent uptick in stock performance, attributed to advancements in health technology and increased demand for pharmacy services. The NYSE Health Care Index has risen by 1.2%, indicating a favorable climate for health-related investments. However, Walgreens must navigate the complexities of its restructuring while competing against agile peers to regain investor confidence and drive growth in a challenging market environment. - Funds were net buyers of $WBA during the previous reporting quarter. - Top 5 funds with large holdings in $WBA: - Candlestick Cap, MV: $86MM. New position. Fund Rank: 81% - Glazer Capital,, MV: $57MM. New position. Fund Rank: 75% - Rubric Capital Management LP, MV: $56MM. Fund Rank: 78% www.rubriccapital.com - Adage Capital P, MV: $22MM. New position. Fund Rank: 79% www.adagecapital.com - Philosophy Capital Management, MV: $14MM. New position. Fund Rank: 69% www.philosophycap.com - Last 10 days performance: 0% - Last 30 days performance: 1% - Last 90 days performance: 2% Some of the latest news articles: - Title: National Advertising Division Finds P&G’s Claims for Crest Gum Detoxify Supported Publication Date: 6/20/2025 2:02:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/national-advertising-division-finds-p-140200602.html?.tsrc=rss - Title: LiveRamp Holdings, Inc. (RAMP) Partners with Walgreens Advertising Group to Leverage First-Party Data Publication Date: 6/19/2025 6:29:55 AM, Source: yahoo URL: https://finance.yahoo.com/news/liveramp-holdings-inc-ramp-partners-062955991.html?.tsrc=rss - Title: Is Cracker Barrel Old Country Store (CBRL) Stock Outpacing Its Retail-Wholesale Peers This Year? Publication Date: 6/18/2025 1:40:02 PM, Source: yahoo URL: https://finance.yahoo.com/news/cracker-barrel-old-country-store-134002574.html?.tsrc=rss - Title: GMS (GMS) Q4 Earnings and Revenues Beat Estimates Publication Date: 6/18/2025 11:10:02 AM, Source: yahoo URL: https://finance.yahoo.com/news/gms-gms-q4-earnings-revenues-111002740.html?.tsrc=rss Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal.
0 · Reply
Errorsmith
Errorsmith Jun. 20 at 8:57 PM
$WBA Didn’t expect Tim Wentworth to sell you all out to private equity, he seemed like a stand-up guy. Then he took a rubber chicken to the backs of retail investors who believed in him, what a shame.
1 · Reply
TheGreatestOfAllTrades
TheGreatestOfAllTrades Jun. 20 at 7:23 PM
$WBA and $PEP both present strong technical chart positions—however, only one is showing clear forward momentum heading into next year: $PEP. In my view, Walgreens’ decision to pursue a private transition reflects a significant setback for shareholder value. In contrast, PepsiCo continues to demonstrate strong fundamentals and strategic clarity. 📈 Based on recent press releases and consistent profitability, $PEP stands out as a solid choice for near-, mid-, and long-term options strategies. For more curated trade ideas and market insights, follow @greatestofalltradesinvestments and @greatestofalltrades on Instagram. #OptionsTrading #InvestmentStrategy #StockMarket #PEP #WBA #ShareholderValue #GreatestofalltradesInvestments
1 · Reply
Terrordomo80
Terrordomo80 Jun. 20 at 1:00 PM
$WBA it appears if you are voting in favor of the most you can potentially walk away with as a shareholder is $14 ($11 + poss $3 in assets) if they are even worth that much @ this point. With my avg being 13.65 im definitely not in favor of as this entire deal has been a a sham from the start and Walgreens mgmt just folded and gave up. There's no reason with their footprint they couldnt have followed in CVSs direction and turned themselves around at least to a more favorable position then they were in 4 months ago when the deal was announced...this is complete bs...
1 · Reply
FKStockTwitz
FKStockTwitz Jun. 18 at 3:35 PM
$WBA When is the deal neither way suppose to be announced?
1 · Reply
Widditwiddit
Widditwiddit Jun. 18 at 2:09 PM
$WBA voted no. Disrespectful merger to shareholders
0 · Reply
ZacksResearch
ZacksResearch Jun. 18 at 1:41 PM
🚀 $CVS is up 53.7% in 2025 — what's driving the surge? 🩺 Strong operational performance with a boost from digital innovation and strategic leadership 🏛️ Regulatory tailwinds as Senate removes proposed PBM and Medicare Advantage constraints 📈 Outperforming the Medical sector, S&P 500, and peers like $HLF and $WBA Opportunity assessment here 👉 https://www.zacks.com/commentary/2507529/cvs-surges-on-regulatory-relief-medicare-advantage-push-time-to-buy?cid=sm-stocktwits-2-2507529-body&ADID=SYND_STOCKTWITS_TWEET_2_2507529_BODY
0 · Reply
Hotresearchsgoldenage
Hotresearchsgoldenage Jun. 18 at 11:51 AM
$WBA voted yes !
0 · Reply
DerekQuick
DerekQuick Jun. 18 at 7:39 AM
$WBA No voting = a no vote fyi ;) no way would i vote for approving a steal like this. Could be $20 without a deal. PBM reform coming = major wba margin gain.
1 · Reply
ChessGM
ChessGM Jun. 18 at 12:30 AM
$WBA Heads up alert! upcoming earnings on Thursday, 6/26/2025 for $WBA Bearish (2.5) Walgreens Boots Alliance (WBA) is navigating a challenging landscape as it prepares for its acquisition by Sycamore Partners, a move that underscores the company’s recent struggles and reflects a need for strategic repositioning. The firm’s stock has recently been fluctuating around the $11 mark, with a P/E ratio of approximately 8.5, indicating that it is undervalued relative to its earnings potential. The company has reported a staggering decline in its market capitalization, from $100 billion to roughly $10 billion, largely attributed to a decade of poor strategic decisions, including unsuccessful mergers and a failure to adapt to retail dynamics. Analysts have projected a negative EPS growth over the next year, with revenue forecasts declining, particularly as competition intensifies in the pharmacy sector. Comparisons to industry peers, such as CVS and Rite Aid, reveal that Walgreens is lagging behind, especially as Rite Aid faces bankruptcy challenges, further complicating the competitive landscape. Looking ahead to upcoming earnings reports, expectations remain tepid. Analysts are forecasting a potential decline in same-store sales and overall revenue, with consensus estimates suggesting modest earnings growth at best. Historically, Walgreens has been resilient but has struggled to maintain consistent performance amid evolving consumer preferences and economic pressures. The anticipated impact of the Sycamore Partners acquisition may provide a much-needed turning point, but analysts remain cautious, urging investors to consider the inherent risks associated with such a significant transition. In terms of sector performance, the healthcare sector has shown resilience, with a recent uptick in the NYSE Health Care Index by 1.2%. However, Walgreens’ position within this sector is precarious, overshadowed by its peers and the broader market dynamics. While the healthcare sector continues to grow, Walgreens must address its operational inefficiencies and strategic misalignments to regain investor confidence and ensure sustainable growth moving forward. - Funds were net buyers of $WBA during the previous reporting quarter. - Top 5 funds with large holdings in $WBA: - Candlestick Cap, MV: $86MM. New position. Fund Rank: 80% - Glazer Capital,, MV: $57MM. New position. Fund Rank: 82% - Rubric Capital Management LP, MV: $56MM. Fund Rank: 77% www.rubriccapital.com - Adage Capital P, MV: $22MM. New position. Fund Rank: 79% www.adagecapital.com - Philosophy Capital Management, MV: $14MM. New position. Fund Rank: 69% www.philosophycap.com - Last 10 days performance: 1% - Last 30 days performance: 1% - Last 90 days performance: 2% Some of the latest news articles: - Title: Walgreens Boots Alliance (WBA) Announces Definitive Agreement to be Acquired by Sycamore Partners Publication Date: 6/17/2025 3:22:41 PM, Source: yahoo URL: https://finance.yahoo.com/news/walgreens-boots-alliance-wba-announces-152241993.html?.tsrc=rss - Title: Walgreens’ lost decade: How M&A mania and retail neglect shrunk a $100 billion giant to a $10 billion private equity gamble Publication Date: 6/17/2025 11:00:00 AM, Source: yahoo URL: https://finance.yahoo.com/news/walgreens-lost-decade-m-mania-110000891.html?.tsrc=rss - Title: Factbox-CEO moves between industries Publication Date: 6/16/2025 12:59:52 PM, Source: yahoo URL: https://finance.yahoo.com/news/factbox-ceo-moves-between-industries-125952262.html?.tsrc=rss - Title: 1 Unpopular Stock that Deserves a Second Chance and 2 to Steer Clear Of Publication Date: 6/13/2025 4:33:18 AM, Source: yahoo URL: https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-043318238.html?.tsrc=rss Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal.
0 · Reply
Latest News on WBA
The Dark Side Of Dividend Growth Investing

Jun 21, 2025, 8:05 AM EDT - 1 day ago

The Dark Side Of Dividend Growth Investing

ET LEG O PFE T WPC XIFR


Rite Aid Prepares to Sell Remaining Assets

Jun 10, 2025, 6:27 PM EDT - 12 days ago

Rite Aid Prepares to Sell Remaining Assets


Walgreens buyout could change the future of pharmacy care

May 30, 2025, 2:11 PM EDT - 23 days ago

Walgreens buyout could change the future of pharmacy care


Stocks With the Highest Dividend Yields in the S&P 500

May 25, 2025, 5:08 PM EDT - 4 weeks ago

Stocks With the Highest Dividend Yields in the S&P 500

BEN DOW PFE VZ


Avoid These Dividend Disasters Before It's Too Late

May 23, 2025, 8:15 AM EDT - 4 weeks ago

Avoid These Dividend Disasters Before It's Too Late

AMGN BMY COP CVS CVX DLR GNL


Unlike CVS, Walgreens Only Interested In Rite Aid Patient Files

May 22, 2025, 11:15 AM EDT - 4 weeks ago

Unlike CVS, Walgreens Only Interested In Rite Aid Patient Files

CVS


Walgreens Ups Use of Robotics With New Micro-Fulfillment Center

May 20, 2025, 12:54 PM EDT - 4 weeks ago

Walgreens Ups Use of Robotics With New Micro-Fulfillment Center


Walgreens Reportedly Upping Use of Robot-Powered Pharmacies

May 12, 2025, 9:06 AM EDT - 5 weeks ago

Walgreens Reportedly Upping Use of Robot-Powered Pharmacies


Walgreens: Acquisition Is The Best-Case Scenario For The Company

Apr 15, 2025, 3:43 PM EDT - 2 months ago

Walgreens: Acquisition Is The Best-Case Scenario For The Company


All 30 Dow Jones Stocks Ranked: Buy, Sell or Hold?

Apr 13, 2025, 4:43 PM EDT - 2 months ago

All 30 Dow Jones Stocks Ranked: Buy, Sell or Hold?

AAPL AMZN DOW MSFT NVDA SHW


Walgreens Boots Alliance: Last Change To Buy

Apr 10, 2025, 11:47 AM EDT - 2 months ago

Walgreens Boots Alliance: Last Change To Buy


Crude Oil Gains 1%; Walgreens Posts Upbeat Earnings

Apr 8, 2025, 12:11 PM EDT - 2 months ago

Crude Oil Gains 1%; Walgreens Posts Upbeat Earnings


Walgreens Sales Rise on U.S. Retail Pharmacy Segment Growth

Apr 8, 2025, 7:49 AM EDT - 2 months ago

Walgreens Sales Rise on U.S. Retail Pharmacy Segment Growth


ChessGM
ChessGM Jun. 20 at 11:41 PM
$WBA "Heads up alert! upcoming earnings on Thursday, 6/26/2025 for $WBA Neutral (5.5) In recent evaluations of Walgreens Boots Alliance (WBA), the company faces significant challenges and strategic shifts as it moves towards privatization following a definitive agreement with Sycamore Partners valued at $23.7 billion. The transaction is positioned as a means to revitalize a company that has seen its market capitalization shrink dramatically from its peak. Key financial metrics for WBA reveal a Price-to-Earnings (P/E) ratio that reflects a struggling retail environment. The company has reported earnings per share (EPS) growth that has been inconsistent, with analysts projecting modest revenue forecasts as it navigates a competitive landscape against peers like CVS and Rite Aid. Walgreens has also struggled with operational efficiency and strategic missteps that have contributed to a decade of stagnation. However, its recent push towards automation and the expansion of micro-fulfillment centers could signal a shift in operational strategy that might enhance its efficiency and service delivery. Regarding upcoming earnings reports, analysts are cautiously optimistic. Historical performance shows a mixed bag, with some quarters outperforming expectations while others have underwhelmed. Analyst consensus estimates indicate that the upcoming earnings report may reflect a slight improvement in revenue, driven by cost-saving initiatives and increased automation in pharmacy operations. However, the overall sentiment suggests that while there may be a recovery in certain metrics, the potential impact of the acquisition and the need for a robust turnaround strategy weigh heavily on future performance. The healthcare retail sector, in which WBA operates, has shown resilience with a recent uptick in stock performance, attributed to advancements in health technology and increased demand for pharmacy services. The NYSE Health Care Index has risen by 1.2%, indicating a favorable climate for health-related investments. However, Walgreens must navigate the complexities of its restructuring while competing against agile peers to regain investor confidence and drive growth in a challenging market environment. - Funds were net buyers of $WBA during the previous reporting quarter. - Top 5 funds with large holdings in $WBA: - Candlestick Cap, MV: $86MM. New position. Fund Rank: 81% - Glazer Capital,, MV: $57MM. New position. Fund Rank: 75% - Rubric Capital Management LP, MV: $56MM. Fund Rank: 78% www.rubriccapital.com - Adage Capital P, MV: $22MM. New position. Fund Rank: 79% www.adagecapital.com - Philosophy Capital Management, MV: $14MM. New position. Fund Rank: 69% www.philosophycap.com - Last 10 days performance: 0% - Last 30 days performance: 1% - Last 90 days performance: 2% Some of the latest news articles: - Title: National Advertising Division Finds P&G’s Claims for Crest Gum Detoxify Supported Publication Date: 6/20/2025 2:02:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/national-advertising-division-finds-p-140200602.html?.tsrc=rss - Title: LiveRamp Holdings, Inc. (RAMP) Partners with Walgreens Advertising Group to Leverage First-Party Data Publication Date: 6/19/2025 6:29:55 AM, Source: yahoo URL: https://finance.yahoo.com/news/liveramp-holdings-inc-ramp-partners-062955991.html?.tsrc=rss - Title: Is Cracker Barrel Old Country Store (CBRL) Stock Outpacing Its Retail-Wholesale Peers This Year? Publication Date: 6/18/2025 1:40:02 PM, Source: yahoo URL: https://finance.yahoo.com/news/cracker-barrel-old-country-store-134002574.html?.tsrc=rss - Title: GMS (GMS) Q4 Earnings and Revenues Beat Estimates Publication Date: 6/18/2025 11:10:02 AM, Source: yahoo URL: https://finance.yahoo.com/news/gms-gms-q4-earnings-revenues-111002740.html?.tsrc=rss Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal.
0 · Reply
Errorsmith
Errorsmith Jun. 20 at 8:57 PM
$WBA Didn’t expect Tim Wentworth to sell you all out to private equity, he seemed like a stand-up guy. Then he took a rubber chicken to the backs of retail investors who believed in him, what a shame.
1 · Reply
TheGreatestOfAllTrades
TheGreatestOfAllTrades Jun. 20 at 7:23 PM
$WBA and $PEP both present strong technical chart positions—however, only one is showing clear forward momentum heading into next year: $PEP. In my view, Walgreens’ decision to pursue a private transition reflects a significant setback for shareholder value. In contrast, PepsiCo continues to demonstrate strong fundamentals and strategic clarity. 📈 Based on recent press releases and consistent profitability, $PEP stands out as a solid choice for near-, mid-, and long-term options strategies. For more curated trade ideas and market insights, follow @greatestofalltradesinvestments and @greatestofalltrades on Instagram. #OptionsTrading #InvestmentStrategy #StockMarket #PEP #WBA #ShareholderValue #GreatestofalltradesInvestments
1 · Reply
Terrordomo80
Terrordomo80 Jun. 20 at 1:00 PM
$WBA it appears if you are voting in favor of the most you can potentially walk away with as a shareholder is $14 ($11 + poss $3 in assets) if they are even worth that much @ this point. With my avg being 13.65 im definitely not in favor of as this entire deal has been a a sham from the start and Walgreens mgmt just folded and gave up. There's no reason with their footprint they couldnt have followed in CVSs direction and turned themselves around at least to a more favorable position then they were in 4 months ago when the deal was announced...this is complete bs...
1 · Reply
FKStockTwitz
FKStockTwitz Jun. 18 at 3:35 PM
$WBA When is the deal neither way suppose to be announced?
1 · Reply
Widditwiddit
Widditwiddit Jun. 18 at 2:09 PM
$WBA voted no. Disrespectful merger to shareholders
0 · Reply
ZacksResearch
ZacksResearch Jun. 18 at 1:41 PM
🚀 $CVS is up 53.7% in 2025 — what's driving the surge? 🩺 Strong operational performance with a boost from digital innovation and strategic leadership 🏛️ Regulatory tailwinds as Senate removes proposed PBM and Medicare Advantage constraints 📈 Outperforming the Medical sector, S&P 500, and peers like $HLF and $WBA Opportunity assessment here 👉 https://www.zacks.com/commentary/2507529/cvs-surges-on-regulatory-relief-medicare-advantage-push-time-to-buy?cid=sm-stocktwits-2-2507529-body&ADID=SYND_STOCKTWITS_TWEET_2_2507529_BODY
0 · Reply
Hotresearchsgoldenage
Hotresearchsgoldenage Jun. 18 at 11:51 AM
$WBA voted yes !
0 · Reply
DerekQuick
DerekQuick Jun. 18 at 7:39 AM
$WBA No voting = a no vote fyi ;) no way would i vote for approving a steal like this. Could be $20 without a deal. PBM reform coming = major wba margin gain.
1 · Reply
ChessGM
ChessGM Jun. 18 at 12:30 AM
$WBA Heads up alert! upcoming earnings on Thursday, 6/26/2025 for $WBA Bearish (2.5) Walgreens Boots Alliance (WBA) is navigating a challenging landscape as it prepares for its acquisition by Sycamore Partners, a move that underscores the company’s recent struggles and reflects a need for strategic repositioning. The firm’s stock has recently been fluctuating around the $11 mark, with a P/E ratio of approximately 8.5, indicating that it is undervalued relative to its earnings potential. The company has reported a staggering decline in its market capitalization, from $100 billion to roughly $10 billion, largely attributed to a decade of poor strategic decisions, including unsuccessful mergers and a failure to adapt to retail dynamics. Analysts have projected a negative EPS growth over the next year, with revenue forecasts declining, particularly as competition intensifies in the pharmacy sector. Comparisons to industry peers, such as CVS and Rite Aid, reveal that Walgreens is lagging behind, especially as Rite Aid faces bankruptcy challenges, further complicating the competitive landscape. Looking ahead to upcoming earnings reports, expectations remain tepid. Analysts are forecasting a potential decline in same-store sales and overall revenue, with consensus estimates suggesting modest earnings growth at best. Historically, Walgreens has been resilient but has struggled to maintain consistent performance amid evolving consumer preferences and economic pressures. The anticipated impact of the Sycamore Partners acquisition may provide a much-needed turning point, but analysts remain cautious, urging investors to consider the inherent risks associated with such a significant transition. In terms of sector performance, the healthcare sector has shown resilience, with a recent uptick in the NYSE Health Care Index by 1.2%. However, Walgreens’ position within this sector is precarious, overshadowed by its peers and the broader market dynamics. While the healthcare sector continues to grow, Walgreens must address its operational inefficiencies and strategic misalignments to regain investor confidence and ensure sustainable growth moving forward. - Funds were net buyers of $WBA during the previous reporting quarter. - Top 5 funds with large holdings in $WBA: - Candlestick Cap, MV: $86MM. New position. Fund Rank: 80% - Glazer Capital,, MV: $57MM. New position. Fund Rank: 82% - Rubric Capital Management LP, MV: $56MM. Fund Rank: 77% www.rubriccapital.com - Adage Capital P, MV: $22MM. New position. Fund Rank: 79% www.adagecapital.com - Philosophy Capital Management, MV: $14MM. New position. Fund Rank: 69% www.philosophycap.com - Last 10 days performance: 1% - Last 30 days performance: 1% - Last 90 days performance: 2% Some of the latest news articles: - Title: Walgreens Boots Alliance (WBA) Announces Definitive Agreement to be Acquired by Sycamore Partners Publication Date: 6/17/2025 3:22:41 PM, Source: yahoo URL: https://finance.yahoo.com/news/walgreens-boots-alliance-wba-announces-152241993.html?.tsrc=rss - Title: Walgreens’ lost decade: How M&A mania and retail neglect shrunk a $100 billion giant to a $10 billion private equity gamble Publication Date: 6/17/2025 11:00:00 AM, Source: yahoo URL: https://finance.yahoo.com/news/walgreens-lost-decade-m-mania-110000891.html?.tsrc=rss - Title: Factbox-CEO moves between industries Publication Date: 6/16/2025 12:59:52 PM, Source: yahoo URL: https://finance.yahoo.com/news/factbox-ceo-moves-between-industries-125952262.html?.tsrc=rss - Title: 1 Unpopular Stock that Deserves a Second Chance and 2 to Steer Clear Of Publication Date: 6/13/2025 4:33:18 AM, Source: yahoo URL: https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-043318238.html?.tsrc=rss Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal.
0 · Reply
checks
checks Jun. 17 at 4:38 AM
$WBA Vote no. Deal sucks. Simple as that. If prospects were that dim, would Pessina be tripling his stake? They’ve engineered performance downwards with writedowns and restructuring charges to steal the outstanding shares for a song. While revenue continues to climb!
0 · Reply
Jeremychew
Jeremychew Jun. 16 at 9:51 PM
$WBA (cont) If management alone were the core issue, we might expect to see activist funds stepping in more aggressively. Their relative absence may suggest deeper, more systemic challenges. The Walgreens of the 1990s no longer exists—today’s company faces a radically different operating environment and margin structure. The competitive climate has made Walgreen's model nearly obsolete buoyed by the shopping habits of the older generation. Let’s also be clear: if the merger falls through, a sharp decline in the stock price is a real possibility. Investors who bought in hoping for deal closure could exit quickly. There are no guarantees the stock will recover to $20 per share—and certainly not quickly. Meanwhile, time is not on Walgreens’ side. The company carries a heavy debt load, and refinancing at higher interest rates looms large. This isn't an ideal deal—but it may be the best deal currently available. The alternatives are far from reassuring. Join Sycamore as an LP?
1 · Reply
Jeremychew
Jeremychew Jun. 16 at 9:45 PM
$WBA I voted yes on the merger and meeting proposals, but no on executive compensation—though the latter is primarily advisory. It's important for shareholders to recognize that no alternative offers emerged during the go-shop period, despite ongoing legislative efforts to reform the PBM industry, which should have theoretically sparked more interest if value were being overlooked. Those voting against the deal often cite management’s poor track record and argue that this is a bad deal. But let’s be honest—Walgreens is in a structurally weaker position than it was decades ago. The company paused its dividend yet still operates at a loss, with projected negative free cash flow to the firm. So the question becomes: What gives you confidence that the same leadership team can drive the stock price back to $20? In hindsight, both former and current management have repeatedly misjudged strategic priorities, leading to a cycle of failed bets and forced divestitures.
1 · Reply
executivewife
executivewife Jun. 16 at 12:41 PM
$WBA I didn’t vote.. worth case long term holders getting lil over 11 +3$ did I understood it correctly I’m confused..
1 · Reply
executivewife
executivewife Jun. 16 at 12:36 PM
$WBA what about big boys black rock still involved so is Vanguard? Doubt they would like this price.. Vanguard's involvement with Walgreens Boots Alliance (WBA) is complex - Vanguard's substantial stake in WBA began in Q2 2021, when they acquired 58,948,812 shares, valued at $3.1 billion. - *Recent Purchases*: - In Q3 2023, Vanguard increased its stake by 14.5%, buying 10,962,030 shares, bringing its total holdings to 86,675,198 shares worth $1.927 billion. - In Q4 2024, Vanguard acquired an additional 2,279,495 shares, growing its holdings by 2.7%, with a total of 86,335,084 shares. - *Recent Sales*: - In Q1 2024, Vanguard sold 880,496 shares, reducing its stake by 1.06%. - In Q2 2024, they sold 51,818 shares, decreasing its stake by 0.06%. - *Current Holdings*: As of the latest transaction, Vanguard holds 86,335,084 shares of WBA stock, worth approximately $877 million, representing 0.01% of its overall portfolio holdings.
0 · Reply
shaunlovestiffany
shaunlovestiffany Jun. 15 at 4:44 PM
$WBA I voted NO on all 3.
0 · Reply
RIPPaulie_Wallstreetnuts
RIPPaulie_Wallstreetnuts Jun. 14 at 11:43 PM
$WBA voted no for all 3
0 · Reply
DerekQuick
DerekQuick Jun. 14 at 7:23 PM
$WBA If anyone thinks the 1990s buyout steal is a yes vote they have no clue what they are talking about. Pbm reform is coming that will improve wba margins. The stock would already be $20+ imo without a steal.
0 · Reply
DerekQuick
DerekQuick Jun. 14 at 2:05 AM
$WBA - Oregon’s SB 951 is now law (June 9). It bans corporate and private equity control of physician practices by closing MSO loopholes. Walgreens $WBA and potential buyer Sycamore would be blocked from owning or controlling VillageMD, CityMD, or Summit Medical Group in Oregon. They’d need to divest, spin off, or firewall those operations to comply—potentially weakening the value proposition of the WBA deal. Other states with similar or pending action: Pennsylvania: House passed PE healthcare oversight bill—Senate vote next. Massachusetts, New Mexico, Indiana, Washington: New regulations in 2025 already live. Connecticut: Hospital ownership limits failed, but lawmakers plan 2026 refile. North Carolina: SB 570 targets MSO/physician ownership conflict. California, Minnesota, Illinois, New York, Colorado, Texas: Mixed progress; trend is growing. Going to mess up any close on the deal. This deal should end soon.... Easily get to $20+ with PBM reform
0 · Reply
Arpsman
Arpsman Jun. 14 at 12:59 AM
$WBA Lots voting no on this one. Of course Pessina is voting yes, he's gonna own half the company (vs 17 percent )when it all said and done if it goes through. Don't we all wish we could get that deal? Just pledge our shares to newco and triple our equity. On a company with a 5x TEV/EBITDA Shows you what Sycamore really thinks it worth.
1 · Reply
executivewife
executivewife Jun. 13 at 6:27 PM
$WBA it’s 341 pages proxy- anyone had a chance to review it?
0 · Reply
Bigguy224
Bigguy224 Jun. 13 at 4:03 PM
$WBA time to roll out on this one. They are struggling and can’t pay dividends anymore. Gotta learn to read the signs of a company doing poorly in generating profits.
0 · Reply